Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.05%, therapeutically equivalent to the Reference Listed Drug (RLD), RESTASIS (cyclosporine ophthalmic emulsion) 0.05%.
Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
According to IQVIA, the US market for cyclosporine ophthalmic emulsion generated sales of approximately USD1.9bn in the 12 months from February 2025 to January 2026.
Bora received US Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for the product in January 2026.
Hansa Biopharma signs EUR115m IDEFIRIX licensing deal with SERB
Lupin receives tentative FDA approval for Revefenacin Inhalation Solution
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
Akeso reports results from Phase II trial of ligufalimab combination therapy in AML
US FDA approves Datar Cancer Genetics' comprehensive genomic profiling assay for solid tumours
US FDA approves Lupin's Famotidine Injection USP
Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook